PATENT CLAIM ANALYSIS

Application Number: 15906170
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["506", "007000"]

Abstract:
Disclosed herein are biomarkers related to gastric cancer. The presently identified salivary biomarkers create the basis for a gastric cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed gastric cancer assay in clinical, diagnostic and therapeutic uses is also included.

Claim (Index 16):
A method of assessing the efficacy of a therapy on a subject comprising:\n (a) analyzing a first saliva sample from the subject with an assay that specifically detects at least two biomarkers selected from the group consisting of Annexin 1 (ANXA1), Cystatin/Stefin B (CSTB), Semaphorin 4B (SEMA4B), S100 calcium binding protein A10 (S100A10), Periplakin (PPL), Serine peptidase inhibitor, Kazal type 7 (SPINK7), EROL-like, RAN binding protein 9 (RANBP9), CD24, Keratin 6A (KRT6A), Keratin 4 (KRT4), eukaryotic translation initiation factor 3 subunit G (EIF3G), triophosphate isomerase 1 (TPL1), Cystatin-B (CSTB), deleted in malignant brain tumors 1 protein (DMBT1),  Neisseria  sp strain (B33KA_ot020_Y56,  Eikenella corrodens  and  Kingella dentriflicans  and sp clone (DE012_0t012_577_582_AD98,  Streptococcus australis  and sp clone (FN04_ot65_073_Ab83),  Fusobacterium  all species (AD99), miR-140-5p, miR-374a, miR-454, miR-15b, miR-28-5p, or miR-301a, thereby providing a first profile; (b) effecting a therapy on the subject; (c) analyzing a second sailva from the subject with an assay that specifically detects at least two biomarkers selected from the group consisting of Annexin 1 (ANXA1), Cystatin/Stefin B (CSTB), Semaphorin 4B (SEMA4B), S100 calcium binding protein A10 (S100A10), Periplakin (PPL), Serine peptidase inhibitor, Kazal type 7 (SPINK7), EROL-like, RAN binding protein 9 (RANBP9), CD24, Keratin 6A (KRT6A), Keratin 4 (KRT4), eukaryotic translation initiation factor 3 subunit G (EIF3G), triophosphate isomerase 1 (TPL1), Cystatin-B (CSTB), deleted in malignant brain tumors 1 protein (DMBT1),  Neisseria  sp strain (B33KA_ot020_Y56,  Eikenella corrodens  and  Kingella dentriflicans  and sp clone (DE012_0t012_577_582_AD98,  Streptococcus australis  and sp clone (FN04_ot65_073_Ab83),  Fusobacterium  all species (AD99), miR-140-5p, miR-374a, miR-454, miR-15b, miR-28-5p, or miR-301a; thereby providing a second expression profile; (e) comparing the first and second expression profile, thereby assessing the efficacy of a therapy.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 88.0
- Lexical Diversity: 1.33333
- Patent Class: 506.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13607236', '13639756', '14265337', '13009393', '14112684']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5896006580084069
- 35 USC 102 Novelty (BERT): 0.6294154421739557
- Combined Prediction Score: 0.5935821364249618
- Mean Citation Score: 339.451742
- Max Citation Score: 810.4442
- Similarity Product: 514.0715136776925

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test